In one paragraphReview in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Vivek ChauhanDivision of Cancer Immunology and Microbiology, Department of Medicine and Oncology and South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.ORCID 0000-0002-8635-2685 Gaytri MahajanDivision of Cancer Immunology and Microbiology, Department of Medicine and Oncology and South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.
Rakesh KumarDivision of Cancer Immunology and Microbiology, Department of Medicine and Oncology and South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.
Shrikanth S GadadDivision of Cancer Immunology and Microbiology, Department of Medicine and Oncology and South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.ORCID 0000-0003-0030-5472 Subhash C ChauhanDivision of Cancer Immunology and Microbiology, Department of Medicine and Oncology and South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.
Chinnaswamy JagannathDepartment of Pathology and Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, Houston, TX 77030, USA.
Subramanian DhandayuthapaniDivision of Cancer Immunology and Microbiology, Department of Medicine and Oncology and South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.ORCID 0009-0001-4390-3811 Funding
Novel Stem Cell Immunotherapy for MDR-TuberculosisR01AI161015 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ENDSLEY, JANICE J, JAGANNATH, CHINNASWAMY · 2021 to 2025
$4.8MSirtuin -Dependent Regulation of Tuberculosis and HIV Interactions in MacrophagesR01AI184551 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Janice J Endsley, Chinnaswamy Jagannath · 2024 to 2026
$3.8MRegulation of innate immunity by self-adjuvated MRNA vaccinesR01AI184394 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI JAGANNATH, CHINNASWAMY · 2025 to 2025
$2.7MA Novel Hyper-Immunogenic Low Virulent BCG vaccine against TuberculosisR01AI175837 · NIAID · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI SUBRAMANIAN DHANDAYUTHAPANI · 2023 to 2026
$2.0MMolecular basis of BCG vaccine sub-strain heterogeneityR01AI187440 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Jeffrey D. Cirillo, Chinnaswamy Jagannath · 2025 to 2026
$1.5MAnalysis of Divergent Transcripts in Estrogen-Dependent SignalingR16GM149497 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI Shrikanth Gadad · 2023 to 2026
$620kNIAID NIH HHS R01 AI161015NIAID NIH HHS R01 AI175837NIAID NIH HHS R01 AI184394NIAID NIH HHS R01 AI184551NIAID NIH HHS R01 AI187440NIGMS NIH HHS R16 GM149497
6 · The paper itselfAbstract
Tuberculosis (TB), caused by
Indexed as
antigen 85BBCGDNA vaccineimmune responsemRNA vaccineM. tuberculosisrecombinantsubunitvaccine
Identifiers
PMID42797631
PMCPMC13611855
What OpenQuestion holds
Textmetadata
Read underepoch 390